Compare · BLLN vs ILMN
BLLN vs ILMN
Side-by-side comparison of BillionToOne Inc. (BLLN) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLLN and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $29.37B, about 5.1x BLLN ($5.80B).
- Over the past year, BLLN is up 14.8% and ILMN is up 76.5% - ILMN leads by 61.7 points.
- BLLN has been more active in the news (9 items in the past 4 weeks vs 3 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 8 for BLLN).
- Company
- BillionToOne Inc.
- Illumina Inc.
- Price
- $126.01-2.45%
- $194.06-1.49%
- Market cap
- $5.80B
- $29.37B
- 1M return
- +16.83%
- +10.86%
- 1Y return
- +14.84%
- +76.55%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2000
- News (4w)
- 9
- 3
- Recent ratings
- 8
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest BLLN
- Officer Johnson Nancy Joann sold $1,821,628 worth of shares (14,199 units at $128.29) as part of a pre-agreed trading plan, decreasing direct ownership by 67% to 6,900 units (SEC Form 4)
- BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar
- SVP of Laboratory Operations Ten Bosch John Roderick sold $533,330 worth of shares (4,251 units at $125.46) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 29,301 units (SEC Form 4)
- Chief Technology Officer Tsao David exercised 20,000 shares at a strike of $2.80 and sold $2,497,698 worth of shares (20,000 units at $124.88) as part of a pre-agreed trading plan (SEC Form 4)
- BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026
- Chairman and CEO Atay Oguzhan exercised 12,500 shares at a strike of $2.80 and sold $1,576,276 worth of shares (12,500 units at $126.10) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Product Officer Sakakibara Shan Riku exercised 4,000 shares at a strike of $29.82 and sold $1,000,000 worth of shares (8,000 units at $125.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 204,000 units (SEC Form 4)
- Chairman and CEO Atay Oguzhan exercised 26,250 shares at a strike of $2.80 and sold $4,729,379 worth of shares (38,750 units at $122.05) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Johnson Nancy Joann sold $100,056 worth of shares (801 units at $124.91) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 21,099 units (SEC Form 4)
- SVP of Laboratory Operations Ten Bosch John Roderick sold $169,920 worth of shares (1,416 units at $120.00) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 33,552 units (SEC Form 4)
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits